Claims for Patent: 6,399,061

Summary for Patent: 6,399,061

Title:	Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma
Abstract:	Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. Preferred anti-CD20 antibodies are the monoclonal anti-body secreted by ATCC Deposit No. HB11388 and the chimeric anti-CD20 antibody secreted by transfectoma TCAE8 accorded ATCC Deposit No. 69119.
Inventor(s):	Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Rancho Santa Fe, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Santa Fe, CA)
Assignee:	IDEC Pharmaceutical Corporation (San Diego, CA)
Application Number:	08/475,815
Patent Claims:	1. A method for depleting peripheral B cells in a host in need of such treatment comprising administering an amount of the anti-CD20 antibody produced by ATCC deposit number 69119 sufficient to induce B cell depletion. 2. The method of claim 1, wherein said antibody is administered parenterally. 3. The method of claim 2, wherein parenteral administration is selected from the group consisting of intravenous, intramuscular, subcutaneous, rectal, vaginal and intraperitoneal administration. 4. The method of claim 2, wherein said antibody is contained in a carrier selected from the group consisting of sterile saline, sterile buffered water, propylene glycol and combinations thereof. 5. The method of claim 1, wherein the amount sufficient to induce B cell depletion ranges from about 0.001 to 30 mg/kg body weight. 6. The method of claim 5, wherein said dosage ranges from about 0.4 to 20.0 mg/kg body weight. 7. The method of claim 1, which comprises administration of more than one dosage of said anti-CD20 antibody.

Details for Patent 6,399,061

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Acrotech Biopharma Llc	ZEVALIN	ibritumomab tiuxetan	Injection	125019	02/19/2002		2019-06-04

International Patent Family for US Patent 6,399,061

Country	Patent Number	Estimated Expiration
Austria	139900
Austria	196606
Austria	421335
Austria	431158
Australia	5603294